Zinc in PDB 5vp0: Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders

Enzymatic activity of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders

All present enzymatic activity of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders:
3.1.4.17;

Protein crystallography data

The structure of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders, PDB code: 5vp0 was solved by I.D.Hoffman, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 30.00 / 2.20
Space group C 1 2 1
Cell size a, b, c (Å), α, β, γ (°) 166.704, 74.265, 91.171, 90.00, 109.77, 90.00
R / Rfree (%) 21.1 / 23.6

Other elements in 5vp0:

The structure of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders also contains other interesting chemical elements:

Fluorine (F) 12 atoms
Magnesium (Mg) 3 atoms

Zinc Binding Sites:

The binding sites of Zinc atom in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders (pdb code 5vp0). This binding sites where shown within 5.0 Angstroms radius around Zinc atom.
In total 3 binding sites of Zinc where determined in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders, PDB code: 5vp0:
Jump to Zinc binding site number: 1; 2; 3;

Zinc binding site 1 out of 3 in 5vp0

Go back to Zinc Binding Sites List in 5vp0
Zinc binding site 1 out of 3 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders


Mono view


Stereo pair view

A full contact list of Zinc with other atoms in the Zn binding site number 1 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe atom residue distance (Å) B Occ
A:Zn1001

b:31.1
occ:1.00
 OD2 A:ASP697 2.1 22.4 1.0
OD1 A:ASP808 2.1 32.6 1.0
NE2 A:HIS660 2.2 26.4 1.0
NE2 A:HIS696 2.2 28.4 1.0
O A:HOH1133 2.4 37.7 1.0
CD2 A:HIS696 3.0 27.0 1.0
CG A:ASP808 3.1 31.4 1.0
CD2 A:HIS660 3.1 26.9 1.0
CG A:ASP697 3.2 22.5 1.0
CE1 A:HIS660 3.2 26.3 1.0
OD2 A:ASP808 3.3 32.4 1.0
CE1 A:HIS696 3.3 28.9 1.0
OD1 A:ASP697 3.7 22.1 1.0
MG A:MG1002 3.8 31.5 1.0
O A:HOH1107 4.2 34.9 1.0
CG A:HIS696 4.2 28.2 1.0
CG A:HIS660 4.3 25.7 1.0
CD2 A:HIS656 4.3 32.4 1.0
CB A:ASP697 4.3 23.5 1.0
ND1 A:HIS660 4.3 26.2 1.0
ND1 A:HIS696 4.3 30.2 1.0
O A:HOH1134 4.3 26.3 1.0
CB A:ASP808 4.5 32.7 1.0
NE2 A:HIS656 4.6 34.0 1.0
CG2 A:VAL664 4.7 31.3 1.0
O A:HOH1101 4.8 22.0 1.0
CA A:ASP808 4.8 31.7 1.0
O A:ASP808 4.9 29.8 1.0

Zinc binding site 2 out of 3 in 5vp0

Go back to Zinc Binding Sites List in 5vp0
Zinc binding site 2 out of 3 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders


Mono view


Stereo pair view

A full contact list of Zinc with other atoms in the Zn binding site number 2 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe atom residue distance (Å) B Occ
B:Zn1001

b:31.4
occ:1.00
 OD2 B:ASP697 2.1 27.1 1.0
NE2 B:HIS660 2.2 27.1 1.0
OD1 B:ASP808 2.2 30.8 1.0
NE2 B:HIS696 2.3 28.3 1.0
O B:HOH1141 2.3 37.1 1.0
O B:HOH1119 2.5 31.2 1.0
CD2 B:HIS696 3.0 28.2 1.0
CD2 B:HIS660 3.0 27.0 1.0
CG B:ASP808 3.1 31.0 1.0
CG B:ASP697 3.1 28.6 1.0
CE1 B:HIS660 3.2 26.9 1.0
CE1 B:HIS696 3.3 28.4 1.0
OD2 B:ASP808 3.4 36.5 1.0
OD1 B:ASP697 3.7 29.8 1.0
O B:HOH1113 4.0 27.5 1.0
MG B:MG1002 4.1 32.6 1.0
O B:HOH1126 4.2 22.0 1.0
CG B:HIS660 4.2 26.6 1.0
CG B:HIS696 4.2 29.4 1.0
CD2 B:HIS656 4.3 32.8 1.0
ND1 B:HIS660 4.3 26.9 1.0
CB B:ASP697 4.3 28.6 1.0
ND1 B:HIS696 4.4 28.6 1.0
CB B:ASP808 4.5 30.6 1.0
NE2 B:HIS656 4.5 33.5 1.0
CG2 B:VAL664 4.8 31.7 1.0
O B:HOH1102 4.8 20.0 1.0
CA B:ASP808 4.9 29.5 1.0
O B:ASP808 4.9 30.9 1.0

Zinc binding site 3 out of 3 in 5vp0

Go back to Zinc Binding Sites List in 5vp0
Zinc binding site 3 out of 3 in the Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders


Mono view


Stereo pair view

A full contact list of Zinc with other atoms in the Zn binding site number 3 of Discovery of Clinical Candidate N-{(1S)-1-[3-Fluoro-4- (Trifluoromethoxy)Phenyl]-2-Methoxyethyl}-7-Methoxy-2-Oxo-2,3- Dihydropyrido[2,3-B]Pyrazine-4(1H)-Carboxamide (Tak-915), A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders within 5.0Å range:
probe atom residue distance (Å) B Occ
C:Zn1001

b:33.0
occ:1.00
 OD2 C:ASP697 2.1 28.0 1.0
OD1 C:ASP808 2.2 32.2 1.0
NE2 C:HIS660 2.2 31.8 1.0
NE2 C:HIS696 2.2 31.2 1.0
O C:HOH1123 2.3 35.0 1.0
O C:HOH1106 2.5 26.3 1.0
CD2 C:HIS696 3.0 30.3 1.0
CD2 C:HIS660 3.1 32.4 1.0
CG C:ASP808 3.1 32.8 1.0
CG C:ASP697 3.1 30.6 1.0
CE1 C:HIS660 3.2 32.6 1.0
CE1 C:HIS696 3.3 30.9 1.0
OD2 C:ASP808 3.3 33.4 1.0
OD1 C:ASP697 3.7 32.7 1.0
O C:HOH1110 4.1 27.8 1.0
MG C:MG1002 4.1 32.5 1.0
CG C:HIS696 4.2 31.2 1.0
CG C:HIS660 4.2 32.5 1.0
CB C:ASP697 4.3 30.3 1.0
ND1 C:HIS660 4.3 33.0 1.0
ND1 C:HIS696 4.3 31.3 1.0
CD2 C:HIS656 4.3 31.3 1.0
O C:HOH1121 4.3 31.8 1.0
CB C:ASP808 4.5 31.7 1.0
NE2 C:HIS656 4.6 33.0 1.0
CG2 C:VAL664 4.7 30.3 1.0
CA C:ASP808 4.9 31.4 1.0
O C:HOH1103 4.9 25.4 1.0
O C:ASP808 4.9 32.9 1.0

Reference:

S.Mikami, S.Nakamura, T.Ashizawa, I.Nomura, M.Kawasaki, S.Sasaki, H.Oki, H.Kokubo, I.D.Hoffman, H.Zou, N.Uchiyama, K.Nakashima, N.Kamiguchi, H.Imada, N.Suzuki, H.Iwashita, T.Taniguchi. Discovery of Clinical Candidate N-((1S)-1-(3-Fluoro-4-(Trifluoromethoxy)Phenyl) -2-Methoxyethyl)-7-Methoxy-2-Oxo-2,3-Dihydropyrido[2, 3-B]Pyrazine-4(1H)-Carboxamide (Tak-915): A Highly Potent, Selective, and Brain-Penetrating Phosphodiesterase 2A Inhibitor For the Treatment of Cognitive Disorders. J. Med. Chem. V. 60 7677 2017.
ISSN: ISSN 1520-4804
PubMed: 28796496
DOI: 10.1021/ACS.JMEDCHEM.7B00807
Page generated: Wed Dec 16 11:12:04 2020

Last articles

Zn in 8WB0
Zn in 8WAX
Zn in 8WAU
Zn in 8WAZ
Zn in 8WAY
Zn in 8WAV
Zn in 8WAW
Zn in 8WAT
Zn in 8W7M
Zn in 8WD3
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy